NXTMS Nexstim Ltd

Nexstim Plc: Managers’ Transactions, Forss

Nexstim Plc: Managers’ Transactions, Forss

Company Announcement, Helsinki, 25 April 2024 at 1:10 PM (EEST)

Nexstim Plc: Managers’ Transactions, Forss

Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces managers’ transactions as follows:

Person subject to the notification requirement

Name: Martin Forss

Position: Member of the Board/Deputy member

Issuer: Nexstim Oyj

LEI: 743700S7ZI0LNMHZ6Y27

Notification type: INITIAL NOTIFICATION

Reference number: 59500/5/4

____________________________________________

Transaction date: 2024-04-23

Outside a trading venue

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

Name of the instrument: 2024H

Nature of transaction: ACCEPTANCE OF A STOCK OPTION

(X) Linked to stock option programme

Transaction details

(1): Volume: 8500 Unit price: 0 EUR

Aggregated transactions (1):

Volume: 8500 Volume weighted average price: 0 EUR

Further information is available on the website , or by contacting:

Mikko Karvinen, CEO

1

The Company’s Certified Advisor is Carnegie Investment Bank AB (publ).

About Nexstim Plc

Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.

Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.

Nexstim shares are listed on Nasdaq First North Growth Market Finland.

For more information, please visit

Attachment



EN
25/04/2024

Underlying

NXTMSNexstim Ltd

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nexstim Ltd

 PRESS RELEASE
Free
NXTMS NEXSTIM LTD

Nexstim, Inc. and Inomed Inc. Enter into Strategic Alliance Agreement ...

Nexstim, Inc. and Inomed Inc. Enter into Strategic Alliance Agreement for US Market Press release, Helsinki, 3 May 2024, 10 AM (EEST) Nexstim, Inc. and Inomed Inc. Enter into Strategic Alliance Agreement for US Market Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces that Nexstim, Inc. has signed a non-exclusive strategic alliance agreement with Inomed Inc. for the purpose of strengthening the collaboration of Marketing, Sales, and Application Support between both companies in the United States. Both Nexstim and Inomed will attend the American Association of Neurological Surgeon...

May 3, 2024 1 EN
 PRESS RELEASE
Free
NXTMS NEXSTIM LTD

Neurosurgery Customer from Germany Orders Nexstim NBS System 5

Neurosurgery Customer from Germany Orders Nexstim NBS System 5 Press release, Helsinki, 26 April 2024 at 3 PM (EEST) Neurosurgery Customer from Germany Orders Nexstim NBS System 5 Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for a new NBS System 5 from an existing customer hospital in Germany. The system will be used in neurosurgery. The Nexstim Navigated Brain Stimulation (NBS) System 5 is indicated for non-invasive mapping of the primary motor cortex of the brain to its cortical gyrus and localization of cortical areas that do not contain essential speech func...

April 26, 2024 1 EN
 PRESS RELEASE
Free
NXTMS NEXSTIM LTD

Nexstim Plc Business Update Q1 2024

Nexstim Plc Business Update Q1 2024 Press release, Helsinki, 26 April 2024 at 9 AM (EEST) Nexstim Plc Business Update Q1 2024 Nexstim Plc (NXTMH:HEX) (”Nexstim” or ”Company”) announces the key highlights of the Company’s business operations during Q1 2024. CEO Mikko Karvinen’s Business Update In line with our main strategic objective, we have continued to focus on profitable net sales growth. The sales of new systems at the beginning of this year has been slow, which is typical considering that hospitals' budgets focus on purchases towards the end of the year. We continued to grow our D...

April 26, 2024 1 EN
 PRESS RELEASE
Free
NXTMS NEXSTIM LTD

Nexstim Oyj:n liiketoiminnan päivitys, tammi-maaliskuu 2024

Nexstim Oyj:n liiketoiminnan päivitys, tammi-maaliskuu 2024 Lehdistötiedote, Helsinki, 26.04.2024, klo. 09.00 (EEST) Nexstim Oyj:n liiketoiminnan päivitys, tammi-maaliskuu 2024 Nexstim Oyj (NXTMH:HEX) (jäljempänä ”Nexstim” tai ”Yhtiö”) kertoo Yhtiön liiketoiminnan kohokohdista vuoden 2024 ensimmäisellä vuosineljänneksellä. Toimitusjohtaja Mikko Karvisen liiketoiminnan päivitys Strategisen päätavoitteemme mukaisesti olemme alkuvuodesta 2024 jatkaneet keskittymistä kannattavaan liikevaihdon kasvuun. Tämän vuoden alun uusien laitteistojen myynti on ollut hiljaista, mikä on tyypillistä otta...

April 26, 2024 1 EN
 PRESS RELEASE
Free
NXTMS NEXSTIM LTD

Nexstim Plc: Managers’ Transactions, Hildén

Nexstim Plc: Managers’ Transactions, Hildén Company Announcement, Helsinki, 25 April 2024 at 1:15 PM (EEST) Nexstim Plc: Managers’ Transactions, Hildén Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces managers’ transactions as follows: Person subject to the notification requirementName: Timo HildénPosition: Member of the Board/Deputy memberIssuer: Nexstim OyjLEI: 743700S7ZI0LNMHZ6Y27Notification type: INITIAL NOTIFICATIONReference number: 59502/4/4 ____________________________________________Transaction date: 2024-04-23Outside a trading venueInstrument type: FINANCIAL INSTRUME...

April 25, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch